Investigational drugs for treating agitation in persons with dementia

Expert Opinion on Investigational Drugs

Volumn 25, Issue 8, 2016, Pages 973-983

  Garay, Ricardo P ^a   Citrome, Leslie ^b   Grossberg, George T ^c   Cavero, Icilio ^a   Llorca, Pierre Michel ^d  

^a Craven ^*  (France)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Agitation; Alzheimer s disease; aripiprazole; AVP 786; brexpiprazole; citalopram; dementia; ELND005; eltoprazine; nabilone

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; BREXPIPRAZOLE; CITALOPRAM; DEUDEXTROMETHORPHAN; ELND 005; ELTOPRAZINE; INOSITOL; NABILONE; ORM 12741; UNCLASSIFIED DRUG; NEW DRUG;

AGITATION; DEMENTIA; DRUG MECHANISM; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; ANIMAL; DRUG DESIGN; PATHOPHYSIOLOGY; PSYCHOMOTOR AGITATION;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEMENTIA; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; PSYCHOMOTOR AGITATION;

EID: 84978541201     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1193155     Document Type: Review

References (93)

1. J.Ngo, J.M.Holroyd-Leduc Systematic review of recent dementia practice guidelines. Age Ageing. 2015;44:25–33.
2. WAR. World Alzheimer Report 2015. The global impact of dementia. Alzheimer’s Dis Int [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.alz.co.uk/research/world-report-2015
3. A.S.Kelley, K.McGarry, R.Gorges, et al. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163:729–736.
4. J.Cummings, J.Mintzer, H.Brodaty, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27:7–17.•• Provisional clinical and research definition of agitation in cognitive disorders by the International Psychogeriatric Association.
5. F.Panza, V.Solfrizzi, D.Seripa, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:1–8.
6. I.M.Antonsdottir, J.Smith, M.Keltz, et al. Advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2015;16:1649–1656.
7. H.C.Kales, L.N.Gitlin, C.G.Lyketsos. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–769.
8. M.Soto, S.Andrieu, F.Nourhashemi, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2015;27:181–197.
9. C.Salzman, D.Jeste, R.E.Meyer, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69:889–898.
10. M.Steinberg. Isn’t your staff trained to manage my mother? Am J Psychiatry. 2016;173:205–207.
11. C.Ballard, M.Orrell, S.YongZhong, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health for people with dementia (WHELD) program. Am J Psychiatry. 2016;173:252–262.
12. L.N.Gitlin, H.C.Kales, C.G.Lyketsos. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020–2029.
13. H.Ma, Y.Huang, Z.Cong, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42:915–937.
14. C.Ballard, J.Waite. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.
15. L.S.Schneider, K.Dagerman, P.S.Insel. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.
16. E.Sacchetti, C.Turrina, P.Valsecchi. Cerebrovascular accidents in elderly people treated with antipsychotic drugs. Drug Saf. 2010;33:273–288.
17. A.Shah, A.Aftab. Should physicians prescribe antipsychotics in dementia? Psychiatr Ann. 2016;46:97–102.
18. L.Citrome. Atypical antipsychotics, elderly patients, and mortality risk. South Med J. 2007;100:964–965.
19. R.P.Garay, L.Samalin, A.Hameg, et al. Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs. 2015;24:507–517.
20. R.P.Garay, P.-M.Llorca, A.H.Young, et al. Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discov Today. 2014;19:1792–1800.
21. R.P.Garay, M.Bourin, E.de Paillette, et al. Potential serotonergic agents for the treatment of schizophrenia. Expert Opin Investig Drugs. 2015;25:1–12.
22. R.P.Garay, L.Citrome, L.Samalin, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17:1–16.
23. G.H.Holloman, S.L.Zeller. Overview of project BETA: best practices in evaluation and treatment of agitation. West J Emerg Med. 2012;13:1–2.
24. M.P.Wilson, D.Pepper, G.W.Currier, et al. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012;13:26–34.
25. European Medicines Agency. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias [Internet]. 2016 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200830.pdf.
26. European Medicines Agency. Human Medicines. European public assessment reports. Aripiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124.
27. Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Aripiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
28. D.Vancampfort, B.Stubbs, A.J.Mitchell, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347.
29. P.P.De Deyn, A.F.J.Drenth, B.P.Kremer, et al. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2013;14:459–474.
30. L.Citrome, I.Kalsekar, R.A.Baker, et al. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin. 2014;30:1629–1641.
31. S.A.Rappaport, R.N.Marcus, G.Manos, et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10:21–27.
32. K.Maeda, H.Sugino, H.Akazawa, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589–604.
33. K.Maeda, L.Lerdrup, H.Sugino, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605–614.
34. L.Citrome, T.B.Stensbøl, K.Maeda. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15:1219–1229.
35. L.Citrome. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Intl Clin Practice. 2015;69:978–997.
36. Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Brexpiprazole [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
37. A.Cipriani, M.Purgato, T.A.Furukawa, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;7:CD006534–CD.
38. Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Celexa [Internet]. 2014 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020822Orig1s046lbl.pdf.
39. A.P.Porsteinsson, L.T.Drye, B.G.Pollock, et al. Effect of citalopram on agitation in Alzheimer disease: The cited randomized clinical trial. JAMA. 2014;311:682–691.•• The SSRI antidepressant citalopram significantly attenuates patient’s agitation and the associated caregiver distress as compared to placebo.
40. B.G.Pollock, B.H.Mulsant, J.Rosen, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460–465.
41. L.S.Schneider, C.Frangakis, L.T.Drye, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry. 2016;173:465–472. doi:10.1176/appi.ajp.2015.15050648.
42. Avanir. Avanir pharmaceuticals announces initiation of phase III trial of AVP-786 for agitation in patients with Alzheimer’s disease [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.avanir.com/press/avanir-pharmaceuticals-announces-initiation-phase-iii-trial-avp-786-agitation-patients.
43. Food and Drug Administration. Nabilone. Drugs@FDA [Internet]. 2006 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
44. M.J.Passmore. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23:116–117.
45. R.G.Pertwee, A.C.Howlett, M.E.Abood, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62:588–631.
46. E.Aso, I.Ferrer. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol. 2014;5:37.
47. L.Volicer, M.Stelly, J.Morris, et al. Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913–919.
48. S.Walther, R.Mahlberg, U.Eichmann, et al. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacol (Berl). 2006;185:524–528.
49. G.A.H.van den Elsen, A.I.A.Ahmed, R.-J.Verkes, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. 2015;84:2338–2346.
50. G.A.H.van den Elsen, A.I.A.Ahmed, R.-J.Verkes, et al. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015;23:1214–1224.
51. J.Rouru, K.Wesnes, J.Hanninen, et al. Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double-blind, placebo-controlled, parallel group, multicenter, proof-of-concept 12 week study. Neurology. 2013;80:e202.• Randomized clinical trial in patients with moderate Alzheimer’s disease showing significant positive effects on episodic memory.
52. J.O.Rinne, K.Wesnes, J.Hänninen, et al. Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: a randomized, double-blind, proof-of-concept study. J Neurol Sci. 2013;333:e322.
53. J.McLaurin, M.E.Kierstead, M.E.Brown, et al. Cyclohexanehexol inhibitors of A[beta] aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801–808.
54. S.Salloway, R.Sperling, R.Keren, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77:1253–1262.• ELND005 treatment led to reductions in brain myo-inositol levels.
55. P.Tariot, C.Lyketsos, G.Crans, et al. The effects of ELND005 (Scyllo-Inositol) on emergence of neuropsychiatric symptoms (NPS) in mild/moderate Alzheimer’s disease: results from a 78-week phase 2 study (P04.215). Neurology. 2012;78(Meeting Abstracts 1):P04.215.• ELND005 treatment reduces the emergence of neuropsychiatric symptoms.
56. C.Lyketsos, S.Abushakra, E.Liang, et al. Effects of oral ELND005 (scyllo-inositol) on neuropsychiatric symptoms in a 78-week phase 2 study in mild/moderate Alzheimer’s disease (AD): potential role of myo-inositol reduction. Alzheimer’s Dement. 2012;8:S771–S2.• ELND005 treatment reduces the emergence of neuropsychiatric symptoms (potential role of myo-inositol).
57. Transition. Elan and transition therapeutics announce topline summary results of phase 2 study and plans for phase 3 for ELND005 (Scyllo-inositol) [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.transitiontherapeutics.com/media/news.php.
58. B.Olivier, J.Mos, D.Rasmussen. Behavioural pharmacology of the serenic, eltoprazine. Drug Metabol Drug Interact. 1990;8:31–83.
59. H.Sijbesma, J.Schipper, E.R.de Kloet. Eltoprazine, a drug which reduces aggressive behaviour, binds selectively to 5-HT1 receptor sites in the rat brain: an autoradiographic study. Eur J Pharmacol. 1990;177:55–66.
60. Amarantus. Amarantus announces positive phase 2 data for Eltoprazine in Alzheimer’s aggression [Internet]. 2015 [cited 2016 Feb 29]. Available from: http://www.amarantus.com/news/press-releases/detail/2033/amarantus-announces-positive-phase-2-data-for-eltoprazine.
61. Food and Drug Administration. Drugs@FDA (FDA Approved Drug Products). Citalopram hydrobromide [Internet]. 2005 [cited 2016 Feb 29]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
62. J.R.Cirrito, B.M.Disabato, J.L.Restivo, et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968–14973.
63. Y.I.Sheline, T.West, K.Yarasheski, et al. An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236re4–re4.
64. T.Kauppila, M.Grönroos, A.Pertovaara. An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist. Pharmacol Biochem Behav. 1995;52:641–644.
65. J.M.Burns, E.W.Boyer. Antitussives and substance abuse. Subst Abuse Rehabil. 2013;4:75–82.
66. L.P.H.Yang, E.D.Deeks. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs. 2015;75:83–90.
67. European Medicines Agency. Human Medicines. European public assessment reports. Nuedexta [Internet]. 2013 [cited 2016 Feb 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002560/human_med_1652.jsp&mid=WC0b01ac58001d124.
68. J.L.Cummings, C.G.Lyketsos, E.R.Peskind, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242–1254.•• AVP-923 (dextromethorphan/quinidine combination) showed significant efficacy for agitation in patients with Alzheimer’s disease dementia.
69. U.K.Zettl, P.Rommer, P.Hipp, et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord. 2016;9:9–30.
70. I.J.Douglas, L.Smeeth. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.
71. C.-S.Wu, S.-C.Wang, S.S.-F.Gau, et al. Association of stroke with the receptor-binding profiles of antipsychotics - a case-crossover study. Biol Psychiatry. 2013;73:414–421.
72. N.Herrmann, K.L.Lanctôt. Do atypical antipsychotics cause stroke? CNS Drugs. 2005;19:91–103.
73. M.M.Raivio, J.V.Laurila, T.E.Strandberg, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416–424.• Impact of atypical and conventional antipsychotics on mortality and hospital admissions among Finnish elderly institutionalized patients with dementia.
74. M.Defrancesco, J.Marksteiner, W.W.Fleischhacker, et al. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18:pyv055.
75. D.Gallagher, N.Herrmann. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014;74:1747–1755.
76. J.Cummings, T.-J.Lai, S.Hemrungrojn, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016;22:159–166.
77. S.Matsunaga, T.Kishi, N.Iwata. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0123289.
78. A.P.Porsteinsson, J.S.Smith, M.A.Keltz, et al. Can antidepressant medication relieve agitation in Alzheimer’s disease? Expert Rev Neurother. 2014;14:969–971.
79. D.P.Seitz, N.Adunuri, S.S.Gill, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16:CD008191.
80. A.Maher, M.Maglione, S.Bagley, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–1369.
81. J.L.Cummings, M.Mega, K.Gray, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314.
82. P.Aalten, F.R.J.Verhey, M.Boziki, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007;24:457–463.
83. P.Aalten, F.R.Verhey, M.Boziki, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord. 2008;25:1–8.
84. C.Kogut, E.B.Crouse, W.V.R.Vieweg, et al. Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports. Ther Adv Drug Saf. 2013;4:189–198.
85. B.Olivier, R.van Oorschot. 5-HT1B receptors and aggression: a review. Eur J Pharmacol. 2005;526:207–217.
86. W.M.A.Verhoeven, S.Tuinier. Serenics: anti-aggression drugs throughout history. Clin Neuropsychiatr. 2007;4:135–143.
87. S.F.de Boer, J.M.Koolhaas. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005;526:125–139.
88. C.A.ZarateJr, J.B.Singh, P.J.Carlson, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
89. C.Fisch, S.B.Knoebel. Electrocardiographic findings in sertraline depression trials. Drug Invest. 1992;4:305–312.
90. R.H.J.ter Meulen. The ethical basis of the precautionary principle in health care decision making. Toxicol Appl Pharmacol. 2005;207:663–667.
91. D.B.Resnik. The precautionary principle and medical decision making. J Med Philos. 2004;29:281–299.
92. C.L.Allen, U.Bayraktutan. Risk factors for ischaemic stroke. Int J Stroke. 2008;3:105–116.
93. M.J.O’Donnell, D.Xavier, L.Liu, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–123.